Phaseline

Targets › DCK

DCK (Deoxycytidine kinase): drug programs, companies and trials

5 programs from 5 companies in 5 trials: 3 Phase 2, 2 Phase 1; Oncology, Infectious disease; next expected readout Dec 2026.

Phosphorylates the deoxyribonucleosides deoxycytidine, deoxyguanosine and deoxyadenosine. Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. (UniProt, P27707)

Open in Phaseline: the race on DCK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peking Union Medical College HospitalGC
Combination of gemcitabine and cisplatin
RRM1, RRM2, DCK, ERCC1Phase 2Biliary Tract Neoplasms ImmunotherapyJan 2027
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Pracytarabine
Pyrimidine nucleoside analog
DCKPhase 2HCCFeb 2027
CellSight Technologies[18F]F-AraG
Radiolabeled substrate for deoxyguanosine kinase (dGK) and deoxycytidine kinase (dCK), bot
DGK, DCKPhase 2Covid19Oct 2027
TretheraTRE-515
Deoxycytidine kinase (dCK) inhibitor
DCKPhase 1Solid Tumor, AdultDec 2026
Jiangsu Hansoh PharmaceuticalHS-10566
Intravesical gemcitabine delivery system
RRM1, RRM2, DCKPhase 1High-risk Non-muscle-invasive Bladder CancerApr 2028

Conditions

Solid Tumor, Adult (1) Covid19 (1) HCC (1) High-risk Non-muscle-invasive Bladder Cancer (1) Biliary Tract Neoplasms Immunotherapy (1)

Modalities

small molecule (5)

Companies

Trethera (1) CellSight Technologies (1) Xi'an Xintong Pharmaceutical Research Co.,Ltd. (1) Jiangsu Hansoh Pharmaceutical (1) Peking Union Medical College Hospital (1)

Related targets

RRM1 (2) RRM2 (2) DGK (1) ERCC1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.